Across TCGA pan-cancer cohorts, NPY2R RNA is linked to patient survival in 17 of 34 cancer types, making it the most broadly survival-associated NPY2R data layer compared with 5 for mutation status.
The strongest signal is observed in kidney chromophobe (KICH), where higher NPY2R RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated NPY2R expression acts as an unfavorable survival marker, although some lineages such as LUAD and THYM show a favorable association.
KICH, CESC, and LUAD are the cancer types where NPY2R RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.